Trauma is a major cause of mortality and morbidity worldwide. In trauma patients, bleeding is a common and potentially life-threatening complication. Haemostasis agents play a critical role in the treatment of trauma patients by controlling bleeding and reducing the risk of complications.

One commonly used haemostasis agent in the treatment of trauma patients is tranexamic acid (TXA). TXA is an antifibrinolytic agent that works by preventing the breakdown of blood clots. It is administered intravenously to trauma patients to reduce the risk of bleeding complications, such as hemorrhagic shock and death. The use of TXA has been shown to improve outcomes in trauma patients, particularly in those with severe bleeding.

Another haemostasis agent commonly used in the treatment of trauma patients is recombinant factor VIIa (rFVIIa). rFVIIa is a clotting factor that promotes the formation of blood clots. It is administered intravenously to trauma patients with coagulopathy, a condition in which the blood’s ability to clot is impaired. The use of rFVIIa has been shown to reduce the need for blood transfusions and improve outcomes in trauma patients with coagulopathy.

In addition to these agents, there are several other haemostasis agents that are used in the treatment of trauma patients, including prothrombin complex concentrates (PCCs), fibrinogen concentrates, and platelet transfusions. These agents are used to address specific bleeding disorders and can be administered alone or in combination with other.